Modular Synthetic Platform for the Elaboration of Fragments in Three Dimensions for Fragment-Based Drug Discovery
Journal of the American Chemical Society · 13.08.2025 · 147 (32) · 29292-29303
DOI: 10.1021/jacs.5c08786 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Chemical Society, online erschienen am 30.07.2025. Verfasst von Andres R Gomez-Angel und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, University of York, York YO10 5DD, U.K. Hauptthemen laut MEDLINE: Drug Discovery. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UK Research and Innovation, Royal Society, European Commission.
Abstract (Originalsprache)
Fragment-based drug discovery (FBDD) is a key strategy employed in the hit-to-lead phase of pharmaceutical development. The rate-limiting step of this process is often identifying and optimizing synthetic chemistry suitable for fragment elaboration, especially in three dimensions (3-D). To address this limitation, we herein present a modular platform for the systematic and programmable elaboration of two-dimensional (2-D) fragment hits into lead-like 3-D compounds, utilizing nine bifunctional building blocks that explore a range of vectors in 3-D. The building blocks comprise (i) rigid sp3-rich bicyclic cyclopropane-based structures to fix the vectors and (ii) two synthetic handles─a protected cyclic amine and a cyclopropyl N-methyliminodiacetic acid (MIDA) boronate. To validate our approach, we present (i) multigram-scale synthesis of each 3-D building block; (ii) Suzuki-Miyaura cross-coupling reactions of the cyclopropyl BMIDA functionality with aryl bromides; and (iii) N-functionalization (via commonplace medicinal chemistry toolkit reactions) of arylated products to deliver 3-D lead-like compounds. Each building block accesses a distinct 3-D exit vector, as shown by analysis of the lowest energy conformations of lead-like molecules using RDKit, and by X-ray crystallography of pyrimidine methanesulfonamide derivatives. Since the synthetic methodology is established in advance of fragment screening and utilizes robust chemistry, the elaboration of fragment hits in 3-D for biochemical screening can be achieved rapidly. To provide proof-of-concept, starting from the drug Ritlecitinib, the development of inhibitors of Janus kinase 3 (JAK3) around a putative pyrrolopyrimidine 2-D fragment hit was explored, streamlining the discovery of a novel and selective JAK3 inhibitor with IC50 = 69 nM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, University of York, York YO10 5DD, U.K.
- Hit Discovery, Discovery Sciences, R&D, AstraZeneca, 1 Francis Crick Ave, Cambridge CB2 0AA, U.K.
ORCID-Profile: Simon C C Lucas, Peter O'Brien
Förderung
- UK Research and Innovation
- Royal Society
- European Commission
Zitieren
APA
Gomez-Angel, A. R., Klein, H. F., Yao, S. Y., Donald, J. R., Firth, J. D., Appiani, R., Palmer, C. J., Lincoln, J., Lucas, S. C. C., Fusani, L., Storer, R. I., & O'Brien, P. (2025). Modular Synthetic Platform for the Elaboration of Fragments in Three Dimensions for Fragment-Based Drug Discovery. Journal of the American Chemical Society, 147(32), 29292-29303. https://doi.org/10.1021/jacs.5c08786
Vancouver
Gomez-Angel AR, Klein HF, Yao SY, Donald JR, Firth JD, Appiani R, et al. Modular Synthetic Platform for the Elaboration of Fragments in Three Dimensions for Fragment-Based Drug Discovery. Journal of the American Chemical Society. 2025;147(32):29292-29303. doi:10.1021/jacs.5c08786
BibTeX
@article{GomezAngel2025,
author = {Gomez-Angel, Andres R and Klein, Hanna F and Yao, Stephen Y and Donald, James R and Firth, James D and Appiani, Rebecca and Palmer, Cameron J and Lincoln, Joshua and Lucas, Simon C C and Fusani, Lucia and Storer, R Ian and O'Brien, Peter},
title = {Modular Synthetic Platform for the Elaboration of Fragments in Three Dimensions for Fragment-Based Drug Discovery},
journal = {Journal of the American Chemical Society},
year = {2025},
volume = {147},
number = {32},
pages = {29292--29303},
doi = {10.1021/jacs.5c08786}
}
EUVIMED